

FREDUN PHARMACEUTICALS LIMITED

Compassionate Healthcare



CIN No : L24239MH1987PLC043662

November 14, 2017

To,

BSE Ltd.,
Listing Department,
Phiroze Jeejeebhoy Towers,
Dalal Street - Fort,
Mumbai – 400 001

Ref.: BSE Scrip Code - 539730

Subject: Newspaper Advertisement of Unaudited Financials for the Quarter ended September 2017

Dear Sir / Madam,

In compliance to Regulation 47 of SEBI Listing Regulations, 2015; we enclose herewith the copies of the Unaudited Financial Results of the Company for Quarter & Half year ended September 30, 2017; as approved by the Board in its meeting held on Monday, November 13, 2017; published in Navshakti & Free-press Journal on November 14, 2017.

Kindly take the same on your Records.

Thanking you,

For **FREDUN PHARMACEUTICALS LIMITED**

D. Medhan



DIRECTOR

Encl. - A/a

Office Address: Manoj Industrial Premises, G.D. Ambekar Marg, Wadala, Mumbai - 400 031, (INDIA)

Factory Address: 14,15,16, Zorabian Industrial Complex, Vevoor, Palghar (E), Dist: Palghar - 401 404.

Phone: 91-22-4031 8111 Fax: 91-22-4031 8133 E-mail: business@fredungroup.com Web: www.fredungroup.com





FREDUN PHARMACEUTICALS LTD.

CIN: L24239MH1987PLC043662

Registered Office: 26, Manoj Industrial Premises, G.D. Ambekar Marg, Wadala, Mumbai - 400 031

Phone Number: +91 22 4031 8111 Fax: +91 22 4031 8133

Email: business@fredungroup.com | Website: www.fredungroup.com

EXTRACT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED SEPTEMBER 30, 2017

(Rs. In Lacs)

Sr. No.	Particulars	Quarter Ended		Half Year ended	Year ended
		Sept. 2017 (Unaudited)	Sept. 2016 (Unaudited)	Sept. 2017 (Unaudited)	March 2017 (Audited)
1.	Total Income from Operations	1549.69	1037.41	2479.96	5861.00
2.	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items#)	50.64	34.00	95.67	224.98
3.	Net Profit / (Loss) for the period before tax (after Exceptional and / or Extraordinary items#)	50.57	32.79	95.60	222.59
4.	Net Profit / (Loss) for the period after tax (after Exceptional and / or Extraordinary items#)	43.57	32.79	80.60	142.74
5.	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	43.57	32.79	80.60	142.74
6.	Equity Share Capital	294.72	237.45	294.72	237.45
7.	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year	0.00	0.00	0.00	238.55
8.	Earnings Per Share (of Rs. 10/- each) (for continuing and discontinued operations) -				
	1. Basic:	1.47	1.38	2.73	6.01
	2. Diluted:	1.47	1.38	2.73	6.01

Note:

- The above is an extract of the detailed format of Quarterly/Annual Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly / Annual Financial Results are available on the websites of the BSE Ltd. at www.bseindia.com and of the Company at www.fredungroup.com
- The impact on net profit / loss, total comprehensive income or any other relevant financial item(s) due to change(s) in accounting policies shall be disclosed by means of a footnote.
- # - Exceptional and/or Extraordinary items adjusted in the Statement of Profit and Loss in accordance with Ind-AS Rules / AS Rules, whichever is applicable.

For Fredun Pharmaceuticals Limited
Sd/-

Daulat Medhora

Jt. Managing Director

Place : Mumbai

Date : November 13, 2017





FREDUN PHARMACEUTICALS LTD.

CIN: L24239MH1987PLC043662

Registered Office: 26, Manoj Industrial Premises, G.D. Ambekar Marg, Wadala, Mumbai - 400 031

Phone Number: +91 22 4031 8111 Fax: +91 22 4031 8133

Email: business@fredungroup.com | Website: www.fredungroup.com

EXTRACT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED SEPTEMBER 30, 2017

(Rs. In Lacs)

Sr. No.	Particulars	Quarter Ended		Half Year ended	Year ended
		Sept. 2017 (Unaudited)	Sept. 2016 (Unaudited)	Sept. 2017 (Unaudited)	March 2017 (Audited)
1.	Total Income from Operations	1549.69	1037.41	2479.96	5861.00
2.	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items#)	50.64	34.00	95.67	224.98
3.	Net Profit / (Loss) for the period before tax (after Exceptional and / or Extraordinary items#)	50.57	32.79	95.60	222.59
4.	Net Profit / (Loss) for the period after tax (after Exceptional and / or Extraordinary items#)	43.57	32.79	80.60	142.74
5.	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	43.57	32.79	80.60	142.74
6.	Equity Share Capital	294.72	237.45	294.72	237.45
7.	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year	0.00	0.00	0.00	238.55
8.	Earnings Per Share (of Rs. 10/- each) (for continuing and discontinued operations) -				
	1. Basic:	1.47	1.38	2.73	6.01
	2. Diluted:	1.47	1.38	2.73	6.01

Note:

- The above is an extract of the detailed format of Quarterly/Annual Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly / Annual Financial Results are available on the websites of the BSE Ltd. at www.bseindia.com and of the Company at www.fredungroup.com
- The impact on net profit / loss, total comprehensive income or any other relevant financial item(s) due to change(s) in accounting policies shall be disclosed by means of a footnote.
- # - Exceptional and/or Extraordinary items adjusted in the Statement of Profit and Loss in accordance with Ind-AS Rules / AS Rules, whichever is applicable.

For Fredun Pharmaceuticals Limited
Sd/-

Place : Mumbai
Date : November 13, 2017

Daulat Medhora
Jt. Managing Director



Tue, 14 November 2017

epaper.freepressjournal.in//c/23708381

